Printer-friendly: Click to view
  • Summary date: Mar 29 2023 - View Summary

    Contains whereas clauses.  Names the act the Uterine Fibroid Research and Education Act of 2023.  Enacts GS 130A-131.26, pertaining to uterine fibroid research and education. Requires the Department of Health and Human Services (Department), in collaboration with certain entities, to do the following four things:

    • Establish, expand, intensify, and coordinate programs to conduct and support research regarding uterine fibroids, with special emphasis on women who are members of racial and ethnic minority groups known to be  disproportionately affected by uterine fibroids.
    • Collect data on items and services furnished to women receiving Medicaid and other State-funded healthcare services who have been diagnosed with uterine fibroids and uterine fibroids-related symptoms for the purpose of assessing the frequency at which such women are furnished such items and services.
    • Develop, annually update, and disseminate to healthcare providers  information on uterine fibroids for the purpose of ensuring that healthcare providers remain informed about the most current information on uterine fibroids. Such information must include the elevated risk for women who are members of racial and ethnic minority groups to develop uterine fibroids and the range of available options for the treatment of symptomatic uterine fibroids, including non-hysterectomy drugs and devices approved under the  federal Food, Drug, and Cosmetic Act.
    • Beginning April 1, 2024, and annually thereafter, requires the Department to report to the specified NCGA committee on any research and education activities undertaken by the Department pursuant to GS 130A-131.26.

    Effective October 1, 2023.

    Effective July 1, 2023, appropriates $500,000 to the Department in recurring funds for the 2023-24 fiscal year and $500,000 in recurring funds for the 2024-25 fiscal year to conduct the activities listed above.